To assess whether NKG2C+ NK cells are suitable for potential clinical use, in particular for immunotherapy of glioblastoma, we investigated the cytotoxic reaction of expanded NKG2C+ NK cells against K562 cells devoid of HLA class I expression and primary glioblastoma cells with expression of classical HLA molecules. The gene discussed is KLRC2; the disease is glioblastoma.